title: Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.
abstract: OBJECTIVE
  Canagliflozin, a sodium glucose co-transporter 2 inhibitor, has demonstrated glycemic improvements across studies of patients with type 2 diabetes mellitus (T2DM). The impact of canagliflozin on HbA1c lowering was assessed by baseline HbA1c and known duration of T2DM.
  
  
  METHODS
  This post hoc analysis pooled data from patients with T2DM enrolled in four 26-week, placebo-controlled, Phase 3 studies of canagliflozin (N=2313). Change in HbA1c from baseline to Week 26 was assessed in the overall population and in subgroups by baseline HbA1c (<8.0%, 8.0%-<9.0%, and ≥9.0%) and known duration of T2DM (<5 years, 5-<10 years, and ≥10 years).
  
  
  RESULTS
  Relative to placebo, canagliflozin 100 and 300 mg provided greater HbA1c reductions in the overall population. Progressively larger placebo-subtracted reductions in HbA1c with canagliflozin 100 and 300 mg were seen with increasing baseline HbA1c. HbA1c reductions were similar across subgroups based on known duration of T2DM. Both canagliflozin doses were generally well tolerated across subgroups, with a safety and tolerability profile consistent with that seen in Phase 3 studies.
  
  
  CONCLUSIONS
  Canagliflozin provided glycemic improvements in patients with T2DM across a range of baseline HbA1c and known duration of T2DM.
authors: Department of Obesity and Endocrinology, University of Liverpool, Liverpool, United Kingdom. Electronic address: J.P.H.Wilding@liverpool.ac.uk.
authors: John P H
authors: JP
authors: Wilding
authors: Department of Endocrinology, Diabetes, and Metabolic Diseases, Ochsner Medical Center, New Orleans, LA, USA.
authors: Lawrence
authors: L
authors: Blonde
authors: Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital; Division of Endocrinology and Metabolism, University of Toronto, Toronto, ON, Canada.
authors: Lawrence A
authors: LA
authors: Leiter
authors: Hospital Cima, Centro de Investigacíon Clínica San Agustín, San José, Costa Rica.
authors: Sonia
authors: S
authors: Cerdas
authors: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors: Cindy
authors: C
authors: Tong
authors: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors: Jacqueline
authors: J
authors: Yee
authors: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors: Gary
authors: G
authors: Meininger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000068896:Canagliflozin / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000068896:Canagliflozin; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010919:Placebos; C517652:hemoglobin A1c protein, human
keywords: Canagliflozin; Efficacy; Glycemic control; Safety; Sodium glucose co-transporter 2 inhibitor; Type 2 diabetes mellitus